(HRTX) Heron Therapeuti - Ratings and Ratios

Heron Therapeutics, Inc. (NASDAQ:HRTX) is a commercial-stage biotechnology company dedicated to improving patient outcomes through innovative therapeutic solutions. The company leverages its proprietary Biochronomer® drug delivery technology, which enables sustained release of short-acting drugs over days to weeks with a single administration. This technology addresses the limitations of traditional dosing regimens, enhancing patient compliance and therapeutic efficacy.

The companys lead products include SUSTOL® (granisetron), an extended-release injection approved for the prevention of chemotherapy-induced nausea and vomiting (CINV), and CINVANTI™ (aprepitant), an intravenous formulation targeting CINV in highly and moderately emetogenic chemotherapy regimens. Both products address significant unmet needs in oncology supportive care. Heron is also advancing ZYNRELEF™, a fixed-dose combination of bupivacaine and meloxicam, and APONVIE™, an intravenous aprepitant formulation for postoperative nausea and vomiting (PONV). These pipeline assets highlight the companys focus on pain management and gastrointestinal disorders.

Founded in 1983 as A.P. Pharma, Inc., Heron Therapeutics rebranded in January 2014 to reflect its expanded focus on pain management and oncology. Headquartered in Cary, North Carolina, the company has established a strong commercial infrastructure to support its growing portfolio. Its commitment to patient-centric innovation has positioned it as a key player in the biotechnology sector.